Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Licitra

Showing results (271-280 of 311) with videos related to

Pageof 32
Sort By:
Cancers|October 28, 2023
The Role of Carbon Ion Therapy in the Changing Oncology Landscape-A Narrative Review of the Literature and the Decade of Carbon Ion Experience at the Italian National Center for Oncological HadrontherapyEster Orlandi, Amelia Barcellini, Barbara Vischioni, et al.
The Oncologist|June 6, 2018
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck CancerMaura L Gillison, George Blumenschein, Jerome Fayette, et al.
Oral Oncology|June 10, 2018
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expressionRobert L Ferris, George Blumenschein, Jerome Fayette, et al.
The Lancet. Oncology|January 30, 2017
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trialDenis Soulières, Sandrine Faivre, Ricard Mesía, et al.
European Journal of Cancer (Oxford, England : 1990)|November 13, 2021
Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohortPaolo Bossi, Annalisa Trama, Alice Bernasconi, et al.
Endocrine|June 23, 2026
Liquid biopsies for BRAF V600E assessment and monitoring in anaplastic thyroid carcinoma: a real-world study of a tertiary cancer centerElena Colombo, Elisa Ortolan, Stefano Cavalieri, et al.
Oral Oncology|August 27, 2019
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trialRobert Haddad, Joel Guigay, Ulrich Keilholz, et al.
The New England Journal of Medicine|October 11, 2016
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckRobert L Ferris, George Blumenschein, Jerome Fayette, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2023
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaSophie Wildsmith, Weimin Li, Song Wu, et al.
Cancers|July 2, 2021
A Prospectively Validated Prognostic Model for Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck Based on Radiomics of Computed Tomography ImagesSimon A Keek, Frederik W R Wesseling, Henry C Woodruff, et al.
Pageof 32

Showing results (271-280 of 311) with videos related to

Sort By:
Pageof 32
Cancers|October 28, 2023
The Role of Carbon Ion Therapy in the Changing Oncology Landscape-A Narrative Review of the Literature and the Decade of Carbon Ion Experience at the Italian National Center for Oncological HadrontherapyEster Orlandi, Amelia Barcellini, Barbara Vischioni, et al.
The Oncologist|June 6, 2018
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck CancerMaura L Gillison, George Blumenschein, Jerome Fayette, et al.
Oral Oncology|June 10, 2018
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expressionRobert L Ferris, George Blumenschein, Jerome Fayette, et al.
The Lancet. Oncology|January 30, 2017
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trialDenis Soulières, Sandrine Faivre, Ricard Mesía, et al.
European Journal of Cancer (Oxford, England : 1990)|November 13, 2021
Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohortPaolo Bossi, Annalisa Trama, Alice Bernasconi, et al.
Endocrine|June 23, 2026
Liquid biopsies for BRAF V600E assessment and monitoring in anaplastic thyroid carcinoma: a real-world study of a tertiary cancer centerElena Colombo, Elisa Ortolan, Stefano Cavalieri, et al.
Oral Oncology|August 27, 2019
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trialRobert Haddad, Joel Guigay, Ulrich Keilholz, et al.
The New England Journal of Medicine|October 11, 2016
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckRobert L Ferris, George Blumenschein, Jerome Fayette, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2023
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaSophie Wildsmith, Weimin Li, Song Wu, et al.
Cancers|July 2, 2021
A Prospectively Validated Prognostic Model for Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck Based on Radiomics of Computed Tomography ImagesSimon A Keek, Frederik W R Wesseling, Henry C Woodruff, et al.
Pageof 32